SG11201913540VA - Anti-Podoplanin Antibody - Google Patents
Anti-Podoplanin AntibodyInfo
- Publication number
- SG11201913540VA SG11201913540VA SG11201913540VA SG11201913540VA SG11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA SG 11201913540V A SG11201913540V A SG 11201913540VA
- Authority
- SG
- Singapore
- Prior art keywords
- podoplanin antibody
- podoplanin
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019048861 | 2019-03-15 | ||
PCT/JP2019/023682 WO2020188836A1 (en) | 2019-03-15 | 2019-06-14 | Anti-podoplanin antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201913540VA true SG11201913540VA (en) | 2020-10-29 |
Family
ID=72520770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201913540VA SG11201913540VA (en) | 2019-03-15 | 2019-06-14 | Anti-Podoplanin Antibody |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2020150947A (en) |
KR (1) | KR20210141794A (en) |
CN (1) | CN113646332B (en) |
SG (1) | SG11201913540VA (en) |
TW (1) | TW202034953A (en) |
WO (1) | WO2020188836A1 (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5604726B2 (en) * | 2009-07-07 | 2014-10-15 | 国立大学法人京都大学 | Immunoassay for podoplanin |
EP2484697B1 (en) * | 2009-09-30 | 2016-09-14 | Fujifilm RI Pharma Co., Ltd. | Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody |
JP6039428B2 (en) * | 2010-03-04 | 2016-12-07 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Anti-HER2 antibodies and compositions |
KR101981342B1 (en) * | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea antibodies |
US10227407B2 (en) * | 2013-10-10 | 2019-03-12 | Yukinari Kato | Anti-podoplanin antibody |
EP3256494A4 (en) * | 2015-02-10 | 2018-12-05 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
EP3323831B1 (en) | 2015-07-15 | 2023-04-12 | Japanese Foundation For Cancer Research | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
JP2018168068A (en) * | 2015-08-10 | 2018-11-01 | 国立大学法人東北大学 | Anti-podoplanin antibody and antibody-drug complex |
CN106947744B (en) * | 2017-03-14 | 2020-05-05 | 福州迈新生物技术开发有限公司 | Hybridoma cell strain secreting monoclonal antibody against podophyllum protein and application thereof |
WO2018179302A1 (en) * | 2017-03-30 | 2018-10-04 | 国立大学法人東北大学 | Anti-podoplanin antibody |
-
2019
- 2019-06-14 CN CN201980003179.7A patent/CN113646332B/en active Active
- 2019-06-14 KR KR1020197037963A patent/KR20210141794A/en unknown
- 2019-06-14 WO PCT/JP2019/023682 patent/WO2020188836A1/en active Application Filing
- 2019-06-14 SG SG11201913540VA patent/SG11201913540VA/en unknown
- 2019-12-23 TW TW108147262A patent/TW202034953A/en unknown
-
2020
- 2020-04-20 JP JP2020074857A patent/JP2020150947A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202034953A (en) | 2020-10-01 |
WO2020188836A1 (en) | 2020-09-24 |
CN113646332B (en) | 2024-08-23 |
JP2020150947A (en) | 2020-09-24 |
CN113646332A (en) | 2021-11-12 |
KR20210141794A (en) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279321A (en) | Anti-sirpα antibody | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL280780A (en) | Anti-tigit antibodies | |
IL280013A (en) | Anti-il36r antibodies | |
IL279352A (en) | Il-11ra antibodies | |
IL289112A (en) | Anti-tigit antibodies | |
IL278010A (en) | Galectin-10 antibodies | |
IL291068A (en) | Anti-cd73 antibodies | |
IL277030A (en) | Antibodies | |
GB202110263D0 (en) | Anti-btla antibodies | |
IL284584A (en) | Anti-tigit antibodies | |
ZA202101177B (en) | Anti-btla antibody | |
GB201811368D0 (en) | Antibody | |
GB201817172D0 (en) | Antibody | |
GB201905150D0 (en) | Ant-ige antibodies | |
IL281594A (en) | Anti-klrg1 antibodies | |
GB2581174B (en) | Antibodies against hEPCR | |
ZA202108836B (en) | Anti-epha4 antibody | |
EP4083211A4 (en) | Anti-cdcp1 antibody | |
GB201806084D0 (en) | Antibodies | |
GB201917480D0 (en) | Antibodies | |
GB201900732D0 (en) | Antibodies | |
IL289160A (en) | Anti-angpt2 antibodies | |
GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies | |
GB201919062D0 (en) | Antibody |